Lynx Dx

03/27/2026

We’re proud to share that our co‑founder, Dr. Arul Chinnaiyan, has been awarded the 2026 Harrington Prize for Innovation in Medicine.

This prestigious honor recognizes his groundbreaking discovery of the TMPRSS2‑ERG gene fusion, now foundational to precision oncology.

Dr. Chinnaiyan’s work continues to transform how we approach prostate cancer and improve patient outcomes. We are honored to have his leadership and vision at the core of Lynx Dx.

Learn more:

2026 Harrington Prize for Innovation in Medicine recognizes pioneering work in prostate cancer diagnosis and treatment

03/10/2026

We’re on the road this March!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://www.lynxdx.com/my-prostate-score/providers/

02/09/2026

It’s been a great first day at WHX Dubai where we are connecting with fellow molecular diagnostic leaders, investors and potential partners all focused on advancing innovation in patient care.

If you’re attending WHX this week, leave us a note in the comments. We’d love to connect!

----

Learn more about how the Lynx Dx team is shaping the future of precision diagnostics with MyProstateScore 2.0.

• Best-in-Class accuracy
• No DRE required
• At-Home or In-Office Collection

https://www.LynxDx.com/

02/04/2026

We on the road this month! Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE required, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.
https://www.lynxdx.com/my-prostate-score/providers/

01/12/2026

MyProstateScore 2.0 (MPS2) provides patients and providers with best-in-class accuracy.

And with MPS2, patients can screen for prostate cancer in the comfort of their home.

Read more about MPS2’s clinical validation in the Journal of Urology: https://www.lynxdx.com/2025/01/clinical-research-publications/mps2-clinical-validation-non-dre-urine/

01/06/2026

We're on the road this month! Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE required, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.
https://www.lynxdx.com/my-prostate-score/providers/

12/18/2025

New insights presented at show how reflex biomarker testing can lower over-detection and help providers make more confident biopsy decisions.

Click below to read how reflex biomarkers are key to guide next steps after an elevated PSA.

SUO 2025, Prostate Cancer, Over Detection in Prostate Cancer, Reflex Biomarkers in prostate cancer, urine biomarkers for prostate cancer, ProScreen.

12/10/2025

Lynx Dx is proud to sponsor Prostate Cancer Summit 2.0, presented by DrTalks.com. This five-day, online event brings together leading voices to empower men and their care teams with clarity on diagnosis, treatment options, and pathways to better outcomes.

On Day 2, our Chief Medical Officer, Spencer Heaton, will share how MyProstateScore 2.0 (MPS2) is advancing prostate cancer care by giving providers confidence to safely defer biopsy with proven best-in-class accuracy.

Whether you’re a patient seeking answers or a provider looking for the latest innovations, this summit offers valuable insights you won’t want to miss — Dec. 13-17.

Register for FREE today: https://drtalks.com/summit/prostate-cancer/

12/09/2025

Lynx Dx continues to advance innovation in prostate cancer diagnostics, with new findings presented last week at the Society of Urologic Oncology.

Learn more: https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4849

12/01/2025

We’re on the road this December!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://www.lynxdx.com/my-prostate-score/providers/

11/21/2025

A 2024 American Cancer Society survey found that two-thirds of men ages 55–69 aren’t being screened for prostate cancer.

For men with an elevated PSA or abnormal exam results, providers can use Lynx Dx's urine-based risk assessment, MyProstateScore 2.0 (MPS2), to help guide whether a biopsy is needed. And the urine sample can be collected at home or in the doctor’s office.

This , share this post to help us raise prostate cancer awareness!

Learn more: https://www.lynxdx.com/my-prostate-score/providers/